The impact of trauma-center care on mortality and function following pelvic ring and acetabular injuries

ABSTRACT Background: Lower mortality and improved physical function following major polytrauma have been associated with treatment at level-1 trauma centers (TC) compared with that at non-trauma centers (NTC). This study investigates the impact of TC care on outcomes after pelvic and acetabular injuries. Methods: Mortality and quality of life-related measures were compared among patients treated in 18 hospitals with level-1 trauma centers and 51 hospitals without trauma centers in 14 U.S. states. Complete data were obtained on 829 adult trauma patients (18-84 years old) with at least one pelvic ring or acetabular injury (OTA 61 or 62). We used inverse probability of treatment weighting to adjust for observable confounding. Results: After adjustment for case mix, in-hospital mortality was significantly lower at TC versus NTC (RR 0.10, 95% CI 0.02-0.47), as was death by 90 days (RR 0.10, 95% CI 0.02-0.47), and one year (RR 0.21, 95% CI 0.06-0.76) for patients with more severe acetabular injuries (OTA 62-B or 62-C). Patients with combined pelvic ring and acetabular injuries treated at TC had lower mortality by 90 days (RR 0.34, 95% CI 0.14-0.82) and one year (RR 0.30 95% CI 0.14-0.68). Care at TC was also associated with mortality risk reduction for those with unstable pelvic ring injuries (OTA 61-B or 61-C) at one year (RR 0.21, 95%CI 0.06-0.76). Seventy-eight percent of included subjects discharged alive was available for interview at twelve months. Average absolute differences in SF-36 physical functioning and Musculoskeletal Functional Assessment at one year were 11.4 (95%CI 5.3 – 17.4) and 13.2 (1.7 – 24.7) respectively, indicating statistically and clinically significant improved outcomes with TC treatment for more severe acetabular injuries. Conclusions: Mortality is reduced for patients with unstable pelvic and severe acetabular injuries when care is provided in a TC compared to NTC. Moreover, those with severe acetabular fractures experience improved physical function at one year. Patients with these injuries represent a well-defined subset of trauma patients that should be preferentially triaged or transferred to a Level-1 trauma center

Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials

Background: Uncontrolled bleeding is a leading cause of death in trauma. Two randomized, placebo-controlled, double-blind trials (one in blunt trauma and one in penetrating trauma) were conducted simultaneously to evaluate the efficacy and safety of recombinant factor VIIa (rFVIIa) as adjunctive therapy for control of bleeding in patients with severe blunt or penetrating trauma. Methodsd: Severely bleeding trauma patients were randomized to rFVIIa (200, 100, and 100 μg/kg) or placebo in addition to standard treatment. The first dose followed transfusion of the eighth red blood cell (RBC) unit, with additional doses 1 and 3 hours later. The primary endpoint for bleeding control in patients alive at 48 hours was units of RBCs transfused within 48 hours of the first dose. Results: Among 301 patients randomized, 143 blunt trauma patients and 134 penetrating trauma patients were eligible for analysis. In blunt trauma, RBC transfusion was significantly reduced with rFVIIa relative to placebo (estimated reduction of 2.6 RBC units, p = 0.02), and the need for massive transfusion (>20 units of RBCs) was reduced (14% vs. 33% of patients; p = 0.03). In penetrating trauma, similar analyses showed trends toward rFVIIa reducing RBC transfusion (estimated reduction of 1.0 RBC units, p = 0.10) and massive transfusion (7% vs. 19%; p = 0.08). Trends toward a reduction in mortality and critical complications were observed. Adverse events including thromboembolic events were evenly distributed between treatment groups. Recombinant FVIIa resulted in a significant reduction in RBC transfusion in severe blunt trauma. Similar trends were observed in penetrating trauma. The safety of rFVIIa was established in these trauma populations within the investigated dose range. Copyright © 2005 by Lippincott Williams & Wilkins, Inc.Articl